Belmont Global Advisors’s Theriva Biologics TOVX Stock Holding History

Belmont Global Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-40	Closed	-$801K	–	82
2015 Q4	$801K	Sell	40 -23	-37%	-$487K	1.04%	27
2015 Q3	$1.25M	Buy	+63	New	+$1.55M	2.12%	11
2015 Q2	–	Sell	-6	Closed	-$109K	–	117
2015 Q1	$109K	Buy	+6	New	+$107K	0.11%	79
2014 Q3	–	Sell	-3	Closed	-$43K	–	140
2014 Q2	$43K	Sell	3 -8	-73%	-$127K	0.03%	128
2014 Q1	$257K	Sell	11 -132	-92%	-$2.73M	0.22%	100
2013 Q4	$1.92M	Buy	+143	New	+$1.8M	1.55%	16

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Belmont Global Advisors's TOVX Position: Q1 2016 in Review

Belmont Global Advisors sold out of Theriva Biologics (TOVX) in Q1 2016, closing a stake of 40 shares — an estimated $801K sold.

Belmont Global Advisors first reported a position in TOVX in Q4 2013 and held it in 6 quarters. The position peaked at $1.92M in Q4 2013. 56 funds tracked by Wall St. Rank hold TOVX as of Q1 2016.

Belmont Global Advisors reported no remaining Theriva Biologics position as of Q1 2016 after selling out during the quarter.
Belmont Global Advisors sold 40 Theriva Biologics shares in Q1 2016, an estimated $801K.
Belmont Global Advisors first reported a position in Theriva Biologics in Q4 2013 and held it in 6 quarters.
Belmont Global Advisors's Theriva Biologics position peaked at $1.92M in Q4 2013.
56 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2016.

Based on Belmont Global Advisors's 13F filing for Q1 2016, filed 16 May 2016.